Status and phase
Conditions
Treatments
About
The objective of this study is to assess the bioequivalence between Amoxicillin and Clavulanate Potassium for Oral Suspension, 600/42.9 mg/5 mL and Augmentin ES-600™ for Oral Suspension, 600/42.9 mg/5 mL in healthy, male and female subjects, under fasting conditions.
Full description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Healthy, non-smoking male or non-pregnant, non-lactating female subjects, 18 years of age and over.
Body weight within ±15% of the appropriate weight range published in 1993 by Metropolitan Life Insurance Company, Statistical Bureau and body-mass index (BMI) less than 30.
Negative for:
No significant diseases or clinically significant abnormal laboratory values.
No clinically significant findings in the physical examination.
No clinically significant findings in vital sign measurements and 12-lead electrocardiogram (ECG).
Informed of the nature of the study and give written consent prior to receiving any study medication.
Female subjects: surgically steril, post-menopausal or practicing a recognized safe method of contraception (abstention, oral or implanted contraceptives, intra-uterine device or consistent condom plus spermicide use).
Exclusion criteria
Known history or presence of any disease or condition which might compromise the following body systems: immunologic, endocrine, renal, cardiovascular, respiratory, hematologic, gastrointestinal, neurologic, hepatic, psychiatric or dermatologic
More specifically: history or presence of significant: sensitivity to multiple allergens, diarrhea, stomach or intestinal disease, mononucleosis, renal or hepatic dysfunction and asthma.
Known or suspected carcinoma.
Known history or presence of:
On a special diet within 4 weeks prior to drug administration (i.e. a deliberate change in diet for any reason).
Participation in another clinical trial or received an investigational product in the previous 30 days prior to drug administration.
Donation up to 250 mK of blood in the previous 30 days, 251-500 mKL in the previous 45 days, 501-750 mL in the previous 60 days or above 750 mL in the previous 90 days prior to study start.
Requirement of any medication, (prescription and/or over-the-counter) or dietary supplements on a routine basis, with the exception of occasional use of acetaminophen and oral or implanted contraceptives.
Difficulty fasting or consuming the standard prescribed meals.
Primary purpose
Allocation
Interventional model
Masking
48 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal